Lipids & metabolic liver disease
Risks and burdens of incident dyslipidaemia in long COVID: a cohort study
Authors' conclusion
Our findings suggest increased risks and 1-year burdens of incident dyslipidaemia and incident lipid-lowering medications use in the post-acute phase of COVID-19 infection. Post-acute care for those with COVID-19 should involve attention to dyslipidaemia as a potential post-acute sequela of SARS-CoV-2 infection.
Study context
- Population
- US veterans free of dyslipidaemia before cohort enrolment
- Participants
- 51,919 / 2,647,654 / 2,539,941
- Exposure
- COVID-19 vs non-infected contemporary control
- COVID-19n = 51,919
- Contemporary controln = 2,647,654reference
- Historical controln = 2,539,941reference
- Outcome
- Risks (HR) and burdens per 1000 people of incident dyslipidaemia, lipid-lowering medications use, and their composite
- Follow-up
- 12 months
Methodological detailsUS Department of Veterans Affairs national health-care databases, inverse probability weighting, contemporary and historical control groups
- US Department of Veterans Affairs national health-care databases
- Inverse probability weighting
- Contemporary and historical control groups
Main finding
As reported in the abstract
Incident dyslipidaemia (post-acute phase) · 1 year
COVID-19 vs Contemporary controlHazard ratio (95% CI)
Total cholesterol >200 mg/dL
1.26(1.22–1.29)
TG >150 mg/dL
1.27(1.23–1.31)
LDL-C >130 mg/dL
1.24(1.20–1.29)
HDL-C <40 mg/dL
1.20(1.16–1.25)
Burden, per 1000 people at 1 year
- Total cholesterol >200 mg/dL
- 22.46 (95% CI 19.14–25.87)
- TG >150 mg/dL
- 22.03 (95% CI 18.85–25.30)
- LDL-C >130 mg/dL
- 18.00 (95% CI 14.98–21.11)
- HDL-C <40 mg/dL
- 15.58 (95% CI 12.52–18.73)
Observational data: associations, not effects.
Further findings
By care setting of acute infection (non-hospitalised, hospitalised, ICU)
- Risks and burdens increased in a graded fashion corresponding to severity of the acute phase
COVID-19 vs historical control
- Results consistent with contemporary control comparison
Original publication
Risks and burdens of incident dyslipidaemia in long COVID: a cohort study. Lancet Diabetes Endocrinol. Published 6 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →